Author

L. VanBlargan

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Immunology· 2 Microbiology· 2

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 4 Research Focus:host-pathogen & immune response· 4 Organism:human· 3 Assay:proteomics· 2 Organism:mouse· 1 Organism:rat· 1

Frequent Co-Authors

J. E. Crowe· 3 shared A. Boon· 2 shared B. Doranz· 2 shared B. Whitener· 2 shared E. Binshtein· 2 shared E. Davidson· 2 shared E. S. Winkler· 2 shared J. B. Case· 2 shared

Activity by Year

2021-2022 · peak 3/yr

Co-Author Collaboration Network

10 top collaborators · 35 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

3 shared papersImmunology

J. E. Crowe

Mutual co-authors in cluster

Author profile →

4 papers

Recent·Most cited

An antibody targeting the N-terminal domain of SARS-CoV-2 disrupts the spike trimer

N. Suryadevara, A. Shiakolas, L. VanBlargan, E. Binshtein, R. Chen, J. B. Case, K. Kramer, E. Armstrong, L. Myers, A. Trivette, C. Gainza, R. Nargi, C. Selverian, E. Davidson, B. Doranz, , J. E. Crowe

The paper identifies a rare antibody that targets the SARS-CoV-2 spike trimer interface, disrupting viral entry and providing protection in mice.

bioRxiv · Jan 12, 2022Immunology

mRNA-1273 and Ad26.COV2.S vaccines protect against the B.1.621 variant of SARS-CoV-2

T. L. Darling, B. Ying, B. Whitener, L. VanBlargan, T. L. Bricker, C.-Y. Liang, A. Joshi, G. Bamunuarachchi, K. Seehra, A. Schmitz, P. Halfmann, Y. Kawaoka, S. Elbashir, D. K. Edwards, L. Thackray, , A. Boon

This study evaluates the efficacy of mRNA-1273 and Ad26.COV2.S vaccines against the B.1.621 variant in mice and hamsters, showing protection against infection and pathology.

bioRxiv · Dec 29, 2021Microbiology

A potently neutralizing anti-SARS-CoV-2 antibody inhibits variants of concern by binding a highly conserved epitope

L. VanBlargan, L. Adams, Z. Liu, R. E. Chen, P. Gilchuk, S. Raju, B. Smith, H. Zhao, J. B. Case, E. S. Winkler, B. Whitener, L. Droit, I. Aziati, P.-Y. Shi, A. Creanga, , M. Diamond

The paper identifies an antibody that neutralizes all SARS-CoV-2 variants by targeting a conserved epitope on the spike protein.

bioRxiv · Apr 26, 2021Microbiology

Neutralizing and protective human monoclonal antibodies recognizing the N-terminaldomain of the SARS-CoV-2 spike protein

N. Suryadevara, S. Shrihari, P. Gilchuk, L. VanBlargan, E. Binshtein, S. Zost, R. Nargi, R. Sutton, E. S. Winkler, E. C. Chen, M. E. Fouch, E. Davidson, B. Doranz, R. H. Carnahan, L. Thackray, , J. E. Crowe

The paper identifies two NTD-specific human mAbs with neutralizing activity against SARS-CoV-2 and shows they require Fc effector functions for optimal protection.

bioRxiv · Jan 19, 2021Immunology